Phaseline

Targets › PSEN1

PSEN1 (Presenilin-1): drug programs, companies and trials

4 programs from 4 companies in 12 trials: 6 Phase 1, 5 Phase 2, 1 Phase 4; Oncology, Other; next expected readout Mar 2027.

Catalytic subunit of the gamma-secretase complex, an endoprotease complex that catalyzes the intramembrane cleavage of integral membrane proteins such as Notch receptors and APP (amyloid-beta precursor protein). Requires the presence of the other members of the gamma-secretase complex for protease activity. (UniProt, P49768)

Open in Phaseline: the race on PSEN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyNirogacestat
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 4Desmoid TumorMay 2027
Children's Oncology GroupNirogacestat Hydrobromide
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 2Desmoid FibromatosisDec 2032
GSKNirogacestat
Gamma-secretase inhibitor
APH1A, PSENEN, APH1B, PSEN1, NCSTNPhase 1Multiple Myeloma; Tumor; Desmoid Tumor; AIDS-Related Kaposi SarcomaMar 2027
ImmunomeVaregacestat
Presenilin-1 (PS1) inhibitor; gamma-secretase inhibitor
PSEN1Phase 1HealthyMay 2027

Conditions

Multiple Myeloma (5) Desmoid Tumor (3) Tumor (1) AIDS-Related Kaposi Sarcoma (1) Healthy (1) Desmoid Fibromatosis (1)

Modalities

small molecule (3), mixed (1)

Companies

GSK (1) Immunome (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) Children's Oncology Group (1)

Related targets

APH1A (3) PSENEN (3) APH1B (3) NCSTN (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.